


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims:

1. (Currently amended) A compound represented by the general formula I




Wherein

the dotted line ---- indicates a single bond or a double bond;

R¹, R², R³, R⁴, R⁵ are independently selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yloxy, ~~or~~ and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, ~~or~~ and NR^zR^w-C₁₋₆-alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, ~~or~~ and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or R^x and R^y together with

the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom; or

R^2 and R^3 together ~~form a heterocycle fused to~~ with the phenyl ring ~~selected from which they are attached form the structure represented by the formula~~



R^6 , R^7 , R^8 , R^9 are independently selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, hydroxy, hydroxy- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yloxy, ~~or~~ and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, ~~or~~ and NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, ~~or~~ and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom;

provided that at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , and R^9 is different from hydrogen;


or a pharmaceutically acceptable salt thereof.

2. (Currently amended) The compound of claim 1, wherein R^1 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yoxy, C_{1-6} -alk(en/yn)ysulfanyl, halo- C_{1-6} -alk(en/yn)yl, ~~or~~ and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, ~~or~~ and NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, ~~or~~ and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w - C_{1-6} -alk(en/yn)yl then the other is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, ~~or~~ and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom[[:]]; ~~typically, R^1 is selected from hydrogen, C_{4-6} -alkyl, or halogen.~~

3. (Currently amended) The compound of ~~any one of claims 1-2~~ claim 1, wherein R^2 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yoxy, C_{1-6} -alk(en/yn)ysulfanyl, and halo- C_{1-6} -alk(en/yn)yl[[:]]; ~~typically, R^2 is selected from hydrogen, C_{4-6} -alkoxy, halo- C_{4-6} -alkyl, C_{4-6} -alkyl, or halogen; more typically, R^2 is selected from hydrogen, or C_{4-6} -alkoxy.~~

4. (Currently amended) The compound of ~~any one of claims 1-3~~ claim 1, wherein R^3 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yoxy, C_{1-6} -alk(en/yn)ysulfanyl, and halo- C_{1-6} -alk(en/yn)yl[[:]]; ~~typically, R^3 is selected from hydrogen, C_{4-6} -alkyl, C_{4-6} -alkoxy, halogen, or halo- C_{4-6} -alkyl; more typically, R^3 is selected from hydrogen, C_{4-6} -alkyl, C_{4-6} -alkoxy, or halogen.~~

5. (Currently amended) The compound of ~~any one of claims 1-2~~ claim 1, wherein R^2 and R^3 together form a heterocycle fused to with the phenyl ring selected from to which they are attached form the structure represented by the formula



6. (Currently amended) The compound of ~~any one of claims 1-5~~ claim 1 wherein R⁴ is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl, and halo-C₁₋₆-alk(en/yn)yl[[:]], ~~typically, R⁴ is selected from hydrogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₁₋₆-alkyl, or halogen; more typically, R⁴ is selected from hydrogen, or C₁₋₆-alkoxy.~~

7. (Currently amended) The compound of ~~any one of claims 1-6~~ claim 1 wherein R⁵ is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl, halo-C₁₋₆-alk(en/yn)yl, ~~or~~ and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, ~~or~~ and NR^zR^w-C₁₋₆-alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, ~~or~~ and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w-C₁₋₆-alk(en/yn)yl then the other is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, ~~or~~ and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom[[:]]. ~~typically, R⁵ is selected from hydrogen, C₁₋₆-alkyl, or halogen.~~

8. (Currently amended) The compound of ~~any one of claims 1-7~~ claim 1 wherein R⁶ is selected from the group consisting of hydrogen, halogen, C₁₋₆-

alk(en/yn)yl, and halo-C₁₋₆-alk(en/yn)yl[:]. ~~typically, R⁶ is selected from hydrogen, or halogen.~~

9. (Currently amended) The compound of ~~any one of claims 1-8~~ claim 1 wherein R⁷ is selected from the group consisting of hydrogen, halogen, C₁₋₆-alk(en/yn)yl, and halo-C₁₋₆-alk(en/yn)yl[:]. ~~typically, R⁷ is selected from hydrogen, or halogen.~~

10. (Currently amended) The compound of ~~any one of claims 1-9~~ claim 1 wherein R⁸ is selected from the group consisting of hydrogen, halogen, C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, ~~or~~ and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, ~~or~~ and NR^zR^w-C₁₋₆-alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, ~~or~~ and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w-C₁₋₆-alk(en/yn)yl then the other is selected the group consisting of from hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, ~~or~~ and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom[:]. ~~typically, R⁸ is selected from hydrogen, halo-C₁₋₆-alkyl, C₁₋₆-alkyl, or halogen.~~

11. (Currently amended) The compound of ~~any one of claims 1-10~~ claim 1 wherein R⁹ is selected from the group consisting of hydrogen, halogen, C₁₋₆-alk(en/yn)yl, and halo-C₁₋₆-alk(en/yn)yl[:]. ~~typically, R⁹ is selected from hydrogen.~~

12. (Currently amended) The compound of ~~any one of claims 1-11~~ claim 1 wherein the dotted line ---- indicates a single bond.

13. (Currently amended) The compound of ~~any one of claims 1-11~~ claim 1 wherein the dotted line ---- indicates a double bond.

14. (Currently amended) The compound of ~~any one of claims 1-13~~ claim 1 wherein the compound of formula I has 1-4 substituents in the phenyl ring(s), selected from any one of R¹-R⁹, which are different from hydrogen, and the remaining substituents are hydrogen.

15. (Currently amended) The compound of claim 1, said compound being selected from the group consisting of:

4-[2-(2,4-Dimethylphenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Chlorophenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Fluoro-2-methylphenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Fluorophenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Methylphenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Methoxyphenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(2,4-Dimethylphenoxy)phenyl]piperidine,
4-[2-(4-Chlorophenoxy)phenyl]piperidine,
4-[2-(4-Fluoro-2-methylphenoxy)phenyl]piperidine,
4-[2-(4-Fluorophenoxy)phenyl]piperidine,
4-[2-(4-Methylphenoxy)phenyl]piperidine,
4-[2-(4-Chloro-2-methyl-phenoxy)-phenyl]-piperidine
4-[2-(3-Chloro-2-methyl-phenoxy)-phenyl]-piperidine
4-[2-(2-Chloro-4-methyl-phenoxy)-phenyl]-piperidine
4-[2-(2,4-Dichloro-phenoxy)-phenyl]-piperidine
4-[2-(Benzo[1,3]dioxol-5-yloxy)-phenyl]-piperidine,
4-[2-(4-Methoxy-2-methyl-phenoxy)-phenyl]-piperidine,
4-[2-(3,4-Dichloro-phenoxy)-phenyl]-piperidine,
4-[2-(3,4-Dimethyl-phenoxy)-phenyl]-piperidine,
4-[2-(2,3,4,5-Tetramethyl-phenoxy)-phenyl]-piperidine,
4-[2-(4-Trifluoromethyl-phenoxy)-phenyl]-piperidine,
4-[2-(4-Methoxy-phenoxy)-phenyl]-piperidine,

4-[2-(2-Chloro-4-methoxy-phenoxy)-phenyl]-piperidine,
4-[2-(3,4-Dimethoxy-phenoxy)-phenyl]-piperidine, and
4-[2-(4-Chloro-3-trifluoromethyl-phenoxy)-phenyl]-piperidine[[.]];
or a pharmaceutically acceptable salt thereof.

16. (Currently amended) A pharmaceutical composition comprising a compound of ~~any one of claims 1-15~~ claim 1 or a pharmaceutically acceptable acid addition salt thereof and at least one pharmaceutically acceptable carrier or diluent.

17. (Currently cancelled) ~~The use of a compound of any one of claims 1 to 15 or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of affective disorders, such as depression, anxiety disorders including general anxiety disorder, social anxiety disorder, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia.~~

18. (Currently amended) A method ~~for the treatment of~~ treating a subject suffering from ~~of an affective disorder[[.]] such as depression, anxiety disorders including general anxiety disorder, social anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia in a living animal body, including a human, comprising administering to a subject~~ a therapeutically effective amount of a compound of any one of claims 1-15 claim 1 or a pharmaceutically acceptable acid addition salt thereof.

19. (Currently cancelled) ~~A compound of any one of claims 1-15 for use as a medicament.~~

20. (New) The compound of claim 2 wherein is selected from the group consisting of hydrogen, C₁₋₆-alkyl, and halogen.

21. (New) The compound of claim 3 wherein R^2 is selected from the group consisting of hydrogen, C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, C_{1-6} -alkyl, and halogen.
22. (New) The compound of claim 21 wherein R^2 is selected from the group consisting of hydrogen, and C_{1-6} -alkoxy.
23. (New) The compound of claim 4 wherein R^3 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, halogen, and halo- C_{1-6} -alkyl.
24. (New) The compound of claim 23 wherein R^3 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy, and halogen.
25. (New) The compound of claim 6 wherein R^4 is selected from the group consisting of hydrogen, C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, C_{1-6} -alkyl, and halogen.
26. (New) The compound of claim 25 wherein R^4 is selected from the group consisting of hydrogen, and C_{1-6} -alkoxy.
27. (New) The compound of claim 7 wherein R^5 is selected from the group consisting of hydrogen, C_{1-6} -alkyl, and halogen.
28. (New) The compound of claim 8 wherein R^6 is selected from the group consisting of hydrogen, and halogen.
29. (New) The compound of claim 9 wherein R^7 is selected from the group consisting of hydrogen, and halogen.
30. (New) The compound of claim 10 wherein R^8 is selected from the group consisting of hydrogen, halo- C_{1-6} -alkyl, C_{1-6} -alkyl, and halogen.

31. (New) The compound of claim 11 wherein R^9 is hydrogen.
32. (New) The method of claim 18 wherein the affective disorder is depression.
33. (New) A method of treating a subject suffering from an anxiety disorder comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable acid addition salt thereof.
34. (New) The method of claim 33 wherein the anxiety disorder is selected from the group consisting of general anxiety disorder, social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia.